Skip to search.
 NZX 50 Down 0.01%

Keryx Biopharmaceuticals Inc. (KERX)

-NasdaqCM
9.67 Down 0.17(1.73%) 3 Jul 08:00
Add to Portfolio
Prev Close:9.84
Open:9.91
Bid:7.00 x 200
Ask:10.40 x 100
1y Target Est:21.60
Beta:6.65
Earnings Date:5 Aug - 10 Aug (Est.)
Day's Range:9.59 - 10.05
52wk Range:8.84 - 18.48
Volume:1,313,691
Avg Vol (3m):1,693,020
Market Cap:1.00b
P/E (ttm):N/A
EPS (ttm):-1.34
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
KERXDown 1.73%1.00b
BAXDown 1.44%20.82b
SHPGUp 1.04%48.32b

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):509.69
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-15) :-0.90
Quarterly EPS Est (Jun-15) :-0.26
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):-0.09

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity ... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback